Xtl Biopharmaceuticals (XTLB) Accounts Payables (2009 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Accounts Payables of $151000.0 for Q4 2025, down 80.89% year-on-year from $790000.0 in Q4 2024, and down 76.33% on a QoQ basis from $638000.0 in Q2 2025.
Xtl Biopharmaceuticals (XTLB) Accounts Payables (2009 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Accounts Payables for 17 consecutive years, with $151000.0 the latest figure, recorded in Q4 2025.
- Quarterly Accounts Payables fell 80.89% year-over-year to $151000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $151000.0 (down 80.89% YoY) and the FY2025 annual result came in at $151000.0, down 80.89% from the prior year.
- Accounts Payables fell to $151000.0 in Q4 2025 per XTLB's latest filing, from $638000.0 in the prior quarter.
- Over the last five years, Accounts Payables for XTLB reached as high as $790000.0 in Q4 2024 and fell as low as $151000.0 in Q4 2025.
- A 5-year average of $286266.7 and a median of $206000.0 in 2023 frame the typical range for Accounts Payables.
- The largest YoY upside for Accounts Payables was 286.67% in 2025 against a maximum downside of 80.89% in 2025.
- Year by year, Accounts Payables stood at $231000.0 in 2021, then fell by 19.05% to $187000.0 in 2022, then increased by 10.16% to $206000.0 in 2023, then soared by 283.5% to $790000.0 in 2024, then plunged by 80.89% to $151000.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $151000.0, $638000.0, and $790000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | 8.64 Mn |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | 151,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 151,000.00 |
| Jun 30, 2025 | 638,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 554,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Mar 31, 2024 | 223,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Sep 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 163,000.00 |
| Mar 31, 2023 | 241,000.00 |
| Dec 31, 2022 | 187,000.00 |
| Sep 30, 2022 | 153,000.00 |
| Jun 30, 2022 | 172,000.00 |
| Dec 31, 2021 | 231,000.00 |
| Jun 30, 2021 | 258,000.00 |
| Dec 31, 2020 | 254,000.00 |
| Dec 31, 2019 | 232,000.00 |
| Dec 31, 2018 | 253,000.00 |
| Dec 31, 2017 | 300,000.00 |
| Dec 31, 2016 | 17,000.00 |